CG Oncology, based in Irvine, Calif., was founded in 2010 by CEO Arthur Kuan. The company, which was last valued at $405 million in September 2022, is a developer of genetically engineered oncolytic immunotherapy treatments for individuals with advanced cancer.

Last September, the company announced an oversubscribed $120 million Series E funding round led by ORI Capital, Longitude Capital and Decheng Capital. The company said it will use the new capital to advance its lead programs toward FDA review and broaden its drug pipeline to address other unmet needs in urologic cancer. Its lead drug candidate, CG0070, has reached Phase 3 testing as a monotherapy for non-muscle invasive bladder cancer.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Register for Details

For more details on financing and valuation for CG Oncology, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about CG Oncology

Forge green plus iconForge green minus icon

What is CG Oncology's funding to date?

CG Oncology has raised $307.89MM to date.
Forge green plus iconForge green minus icon

When was CG Oncology founded?

CG Oncology was founded in 2010.

CG Oncology funding rounds and last known valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
8/2/2023

Series F

$105.02MM raised $XXX.XX $XXX.XX
9/30/2022

Series E

$120MM raised $XXX.XX $XXX.XX
12/10/2020

Series D

$47.3MM raised $XXX.XX $XXX.XX
3/18/2019

Series C

$22MM raised $XXX.XX $XXX.XX
8/5/2015

Series B

$10MM raised $XXX.XX $XXX.XX
7/28/2014

Series A-1

$3.57MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Jun 16, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.